Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 14 | 2026 | 950 | 2.200 |
Why?
|
| Receptors, Antigen, T-Cell | 11 | 2026 | 499 | 1.980 |
Why?
|
| T-Lymphocytes | 15 | 2026 | 1707 | 1.310 |
Why?
|
| Blood Platelets | 2 | 2024 | 313 | 1.180 |
Why?
|
| Oncolytic Virotherapy | 3 | 2020 | 106 | 0.820 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 630 | 0.720 |
Why?
|
| Cellular Senescence | 1 | 2024 | 216 | 0.710 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 90 | 0.680 |
Why?
|
| Genetic Vectors | 2 | 2021 | 892 | 0.660 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 688 | 0.590 |
Why?
|
| Neoplasms | 3 | 2022 | 2975 | 0.520 |
Why?
|
| Apoptosis | 1 | 2024 | 1826 | 0.520 |
Why?
|
| Genetic Therapy | 1 | 2020 | 711 | 0.460 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2026 | 1001 | 0.430 |
Why?
|
| Genetic Engineering | 3 | 2019 | 161 | 0.400 |
Why?
|
| Antigens, Neoplasm | 4 | 2026 | 393 | 0.360 |
Why?
|
| CD28 Antigens | 2 | 2024 | 76 | 0.350 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 189 | 0.350 |
Why?
|
| Cell Line, Tumor | 10 | 2026 | 3713 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 735 | 0.290 |
Why?
|
| Mice | 13 | 2026 | 18160 | 0.290 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2026 | 608 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 688 | 0.260 |
Why?
|
| Immunological Synapses | 1 | 2026 | 32 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1212 | 0.230 |
Why?
|
| Interleukin-18 | 1 | 2026 | 75 | 0.230 |
Why?
|
| Animals | 14 | 2026 | 33660 | 0.230 |
Why?
|
| Natural Killer T-Cells | 1 | 2026 | 91 | 0.210 |
Why?
|
| Adenoviridae | 2 | 2017 | 581 | 0.210 |
Why?
|
| Interleukin-15 | 2 | 2026 | 104 | 0.210 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2024 | 25 | 0.210 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 706 | 0.200 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 79 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 175 | 0.200 |
Why?
|
| Musa | 1 | 2023 | 7 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 150 | 0.190 |
Why?
|
| Humans | 22 | 2026 | 130085 | 0.190 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 5 | 0.180 |
Why?
|
| Dasatinib | 1 | 2022 | 50 | 0.180 |
Why?
|
| Transgenes | 2 | 2021 | 316 | 0.180 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 9 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 55 | 0.170 |
Why?
|
| Interleukin-4 | 2 | 2018 | 144 | 0.170 |
Why?
|
| Clinical Studies as Topic | 1 | 2020 | 11 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 191 | 0.160 |
Why?
|
| Cell Engineering | 1 | 2020 | 21 | 0.160 |
Why?
|
| Plasmids | 1 | 2021 | 444 | 0.160 |
Why?
|
| Cell Survival | 2 | 2019 | 828 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 289 | 0.160 |
Why?
|
| Cyclin A1 | 1 | 2020 | 5 | 0.160 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 21 | 0.160 |
Why?
|
| Leukemia | 1 | 2023 | 375 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1273 | 0.150 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 84 | 0.150 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 80 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2022 | 820 | 0.150 |
Why?
|
| Coculture Techniques | 1 | 2019 | 229 | 0.150 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 133 | 0.150 |
Why?
|
| Immunophenotyping | 1 | 2019 | 332 | 0.140 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 271 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2019 | 194 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 636 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 2597 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4639 | 0.130 |
Why?
|
| Gene Editing | 1 | 2019 | 236 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 40 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2020 | 556 | 0.120 |
Why?
|
| Cytokines | 2 | 2019 | 1332 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 449 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2019 | 2462 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 13 | 0.100 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 27 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 679 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 201 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1906 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 747 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 635 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2026 | 271 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 977 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 3358 | 0.080 |
Why?
|
| Adoptive Transfer | 2 | 2020 | 235 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2026 | 95 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12821 | 0.050 |
Why?
|
| Lectins | 1 | 2023 | 50 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1482 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 11 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 352 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 492 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 639 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2026 | 4645 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 298 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 306 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2020 | 158 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1475 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 758 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1241 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 668 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 351 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 109 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2017 | 55 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 394 | 0.030 |
Why?
|
| Lymphocyte Transfusion | 1 | 2017 | 55 | 0.030 |
Why?
|
| A549 Cells | 1 | 2017 | 48 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 83 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 124 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 237 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2554 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 699 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2885 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1481 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 523 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 583 | 0.020 |
Why?
|
| Female | 4 | 2021 | 70246 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 800 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6067 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2008 | 0.020 |
Why?
|
| Male | 2 | 2020 | 64386 | 0.010 |
Why?
|